NAV

Fosifloxuridine nafalbenamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Fosifloxuridine nafalbenamide
DrugBank Accession Number
DB14859
Background

Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 613.535
Monoisotopic: 613.162544687
Chemical Formula
C29H29FN3O9P
Synonyms
  • Fosifloxuridine nafalbenamide
External IDs
  • NUC-3373
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
4YO6QT3SZ9
CAS number
1332837-31-6
InChI Key
BIOWRMNRHMERIO-ZVAHOJSLSA-N
InChI
InChI=1S/C29H29FN3O9P/c1-18(28(36)39-16-19-8-3-2-4-9-19)32-43(38,42-24-13-7-11-20-10-5-6-12-21(20)24)40-17-25-23(34)14-26(41-25)33-15-22(30)27(35)31-29(33)37/h2-13,15,18,23,25-26,34H,14,16-17H2,1H3,(H,32,38)(H,31,35,37)/t18-,23-,25+,26+,43?/m0/s1
IUPAC Name
benzyl (2S)-2-[({[(2R,3S,5R)-5-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}(naphthalen-1-yloxy)phosphoryl)amino]propanoate
SMILES
C[C@H](NP(=O)(OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O)OC1=C2C=CC=CC2=CC=C1)C(=O)OCC1=CC=CC=C1

References

General References
Not Available
ChemSpider
28666204
ChEMBL
CHEMBL2181367

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentColorectal Adenocarcinoma / Colorectal Cancer / Colorectal Neoplasms / Metastatic Colorectal Cancer (CRC)1
1CompletedTreatmentCancer1
1, 2CompletedTreatmentColorectal Cancer / Colorectal Carcinoma (CRC) / Colorectal Neoplasms1
1, 2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Solid Tumors / Classical Hodgkin's Lymphoma / Endometrial Carcinoma / Esophageal Carcinoma / Gastric Cancer / Malignant Neoplasm / Melanoma / Metastatic Cancer / Microsatellite Instability High Colorectal Cancer / Non-Small Cell Lung Cancer (NSCLC) / Pleural Mesotheliomas / Renal Cell Carcinoma (RCC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Subungual Squamous Cell Carcinoma / Triple-Negative Breast Cancer / Urothelial Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00113 mg/mLALOGPS
logP2.89ALOGPS
logP3.15Chemaxon
logS-5.7ALOGPS
pKa (Strongest Acidic)8.08Chemaxon
pKa (Strongest Basic)-3.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area152.73 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity149.23 m3·mol-1Chemaxon
Polarizability58.73 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pbl-4112972000-00d006ad81084ff5163a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03xr-0012914000-947a76ae16dc53132e32
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001c-8736961000-d419d352d11c19742cf4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01tc-4022931000-d926055db04e50957a00
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9800211000-86662c45b387a3641538
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pic-3290010000-f8ebb1ada0a0567877c8
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 14:31 / Updated at February 21, 2021 18:54